ProShare Advisors LLC diminished its stake in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL – Free Report) by 20.1% throughout the second quarter, Holdings Channel.com experiences. The agency owned 7,053 shares of the specialty pharmaceutical firm’s inventory after promoting 1,773 shares throughout the interval. ProShare Advisors LLC’s holdings in Collegium Pharmaceutical had been value $227,000 as of its most up-to-date submitting with the Securities & Trade Fee.
A number of different institutional traders have additionally purchased and bought shares of COLL. Gladius Capital Administration LP acquired a brand new place in Collegium Pharmaceutical throughout the 2nd quarter valued at about $32,000. nVerses Capital LLC elevated its stake in shares of Collegium Pharmaceutical by 1,600.0% throughout the second quarter. nVerses Capital LLC now owns 1,700 shares of the specialty pharmaceutical firm’s inventory valued at $55,000 after buying a further 1,600 shares throughout the interval. Sheaff Brock Funding Advisors LLC acquired a brand new stake in Collegium Pharmaceutical within the first quarter value roughly $204,000. Gallacher Capital Administration LLC purchased a brand new place in Collegium Pharmaceutical throughout the 1st quarter valued at $223,000. Lastly, China Common Asset Administration Co. Ltd. elevated its place in shares of Collegium Pharmaceutical by 62.1% throughout the 1st quarter. China Common Asset Administration Co. Ltd. now owns 6,120 shares of the specialty pharmaceutical firm’s inventory valued at $238,000 after buying a further 2,344 shares throughout the interval.
Wall Avenue Analysts Forecast Development
A number of analysis analysts not too long ago weighed in on COLL shares. StockNews.com lower Collegium Pharmaceutical from a “strong-buy” ranking to a “purchase” ranking in a analysis observe on Saturday, August thirty first. Needham & Firm LLC reaffirmed a “maintain” ranking on shares of Collegium Pharmaceutical in a analysis observe on Friday, August ninth. Jefferies Monetary Group raised shares of Collegium Pharmaceutical from a “maintain” ranking to a “purchase” ranking and elevated their goal worth for the corporate from $41.00 to $44.00 in a analysis observe on Friday, June seventh. HC Wainwright lifted their worth goal on shares of Collegium Pharmaceutical from $47.00 to $50.00 and gave the inventory a “purchase” ranking in a analysis report on Thursday, September fifth. Lastly, Piper Sandler reiterated a “impartial” ranking and set a $37.00 worth goal (down beforehand from $39.00) on shares of Collegium Pharmaceutical in a analysis report on Friday, August ninth. Two equities analysis analysts have rated the inventory with a maintain ranking and 4 have assigned a purchase ranking to the corporate. In accordance with knowledge from MarketBeat, the inventory at present has a median ranking of “Reasonable Purchase” and a median goal worth of $42.60.
Learn Our Newest Inventory Evaluation on Collegium Pharmaceutical
Insider Exercise at Collegium Pharmaceutical
In different Collegium Pharmaceutical information, EVP Thomas B. Smith bought 9,593 shares of Collegium Pharmaceutical inventory in a transaction on Friday, September thirteenth. The shares had been bought at a median worth of $36.62, for a complete transaction of $351,295.66. Following the completion of the sale, the chief vp now owns 53,816 shares of the corporate’s inventory, valued at $1,970,741.92. This commerce represents a 0.00 % lower of their place. The sale was disclosed in a submitting with the SEC, which is accessible at this hyperlink. In different Collegium Pharmaceutical information, EVP Shirley R. Kuhlmann bought 19,248 shares of Collegium Pharmaceutical inventory in a transaction that occurred on Thursday, September fifth. The shares had been bought at a median worth of $38.30, for a complete worth of $737,198.40. Following the completion of the sale, the chief vp now straight owns 120,161 shares within the firm, valued at $4,602,166.30. The commerce was a 0.00 % lower of their possession of the inventory. The transaction was disclosed in a authorized submitting with the Securities & Trade Fee, which is accessible by way of the SEC web site. Additionally, EVP Thomas B. Smith bought 9,593 shares of the inventory in a transaction on Friday, September thirteenth. The inventory was bought at a median worth of $36.62, for a complete transaction of $351,295.66. Following the transaction, the chief vp now owns 53,816 shares within the firm, valued at roughly $1,970,741.92. This commerce represents a 0.00 % lower of their place. The disclosure for this sale might be discovered right here. 3.98% of the inventory is at present owned by insiders.
Collegium Pharmaceutical Worth Efficiency
COLL inventory opened at $41.86 on Friday. The agency has a 50-day shifting common of $37.22 and a two-hundred day shifting common of $35.55. The agency has a market capitalization of $1.37 billion, a PE ratio of 17.44 and a beta of 0.94. The corporate has a present ratio of 1.11, a fast ratio of 1.04 and a debt-to-equity ratio of 1.71. Collegium Pharmaceutical, Inc. has a one 12 months low of $20.95 and a one 12 months excessive of $42.23.
Collegium Pharmaceutical (NASDAQ:COLL – Get Free Report) final posted its quarterly earnings knowledge on Thursday, August eighth. The specialty pharmaceutical firm reported $1.62 earnings per share for the quarter, topping the consensus estimate of $1.40 by $0.22. Collegium Pharmaceutical had a internet margin of 17.32% and a return on fairness of 107.62%. The agency had income of $145.28 million for the quarter, in comparison with analysts’ expectations of $143.94 million. Throughout the identical interval within the earlier 12 months, the corporate posted $1.13 EPS. The corporate’s quarterly income was up 7.2% in comparison with the identical quarter final 12 months. On common, analysts forecast that Collegium Pharmaceutical, Inc. will submit 5.82 earnings per share for the present 12 months.
Collegium Pharmaceutical Firm Profile
Collegium Pharmaceutical, Inc, a specialty pharmaceutical firm, engages within the improvement and commercialization of medicines for ache administration. Its portfolio consists of Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the administration of ache extreme sufficient to require day by day, around-the-clock, long-term opioid therapy; Nucynta ER and Nucynta IR, that are extended-release and immediate-release formulations of tapentadol, indicated for the administration of acute, extreme, and chronic ache; Belbuca, a buccal movie that incorporates buprenorphine; and Symproic, an oral formulation of naldemedine for the therapy of opioid-induced constipation in grownup sufferers with continual non-cancer ache.
Featured Tales
Need to see what different hedge funds are holding COLL? Go to HoldingsChannel.com to get the most recent 13F filings and insider trades for Collegium Pharmaceutical, Inc. (NASDAQ:COLL – Free Report).
Obtain Information & Scores for Collegium Pharmaceutical Each day – Enter your electronic mail deal with beneath to obtain a concise day by day abstract of the most recent information and analysts’ scores for Collegium Pharmaceutical and associated firms with MarketBeat.com’s FREE day by day electronic mail publication.
